Span Divergent Limited-Notice of the 46th Annual General Meeting of the company scheduled to be held on Monday, September 28, 2026

Span Divergent Ltd. (Formerly Span Diagnostics Ltd.) 9th Floor, Rajhans Bonista, Behind Ram Chowk, Ghod Dod Road, Surat - 395 007, Gujarat, India Phone: +91 261 266 32 32 E-Mail: contact@span.in Date: September 02, 2026 Bombay Stock Exchange Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001 Span Divergent Limited Script Code: 524727 Subject: Submission of Notice of 46th Annual General Meeting (“AGM”) of the Company pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby submit the Notice of the 46th Annual General Meeting (“AGM”) of the Company, scheduled to be held on Monday, September 28, 2026, at 11:30 A.M. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”). The said Notice forms part of the Integrated Annual Report of the Company for the Financial Year 2025-2026. The Notice of the 46th AGM is also available on the website of the Company at www.span.in. The schedule of the AGM and related activities is set out below: Event Date Time Relevant Date/cut-off date to vote for voting on September 21, 2026 NA AGM resolutions Closure of Register of Members and Share From September 22, 2026 to September NA Transfer Books 28, 2026 (both day inclusive) Commencement of remote E-voting September 25,2026 9.00 A.M. End of remote e-voting September 27,2026 5.00 P.M. AGM (through VC/OAVM) September 28,2026 11.30 A.M. Kindly take the above information on your record. Thanking you, Yours faithfully, For Span Divergent Limited Viral Desai Managing Director DIN: 00029219 NOTICE THE MEMBERS OF SPAN DIVERGENT LIMITED NOTICE is hereby given that the 46th Annual General Meeting (AGM) of Shareholders of Span Divergent Limited (Formerly Span Diagnostics Limited) will be held on Monday, September 28, 2026 at 11:30 A.M. Indian Standard Time (IST) through Video Conferencing / Other Audio- Visual Means (‘VC/OAVM”) facility to transact the following businesses: ORDINARY BUSINESS 1. To receive, consider and adopt the Audited Financial Statements including Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditor thereon; and further to consider and pass, with or without modification(s) the following resolution as an Ordinary Resolution: “RESOLVED THAT the Standalone and Consolidated Annual Financial Statements of the Company for the financial year ended March 31, 2026, together with Directors’ Report and the Auditors’ Reports thereon as circulated to the members and presented at the meeting be and are hereby approved and adopted.” 2. To appoint a director in place of Mr. Sanjay Mehta (DIN: 00002817) who retires by rotation and being eligible, offers himself for re- appointment and in this regard to consider and if thought fit, to pass, with or without modification(s) the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013 and relevant rules framed thereunder, including any modification(s) thereto or re-enactment(s) thereof, for the time being in force, Mr. Sanjay Mehta (DIN: 00002817) a Director liable to retire by rotation who offers himself for re-appointment, be re-appointed as a Director of the Company.” SPECIAL BUSINESS 3. Continuation of directorship of Mr. Sanjay Mehta (DIN: 00002817), as Non-Executive Non-Independent Director in terms of Regulation 17(1A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in this regard to consider and if thought fit, to pass, with or without modification the following resolution as a Special Resolution: “RESOLVED THAT pursuant to the provisions of Regulation 17(1A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and other applicable provisions, if any, of the Companies Act, 2013 read with the Rules made thereunder and the Articles of Association of the Company (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), approval of the Members be and is hereby accorded for the continuation of directorship of Mr. Sanjay Mehta (DIN: 00002817), who has attained the age of 75 years on October 20, 2024, as a Non-Executive Non-Independent Director of the Company, liable to retire by rotation, for so long as he continues to hold office as Director in accordance with the provisions of the Companies Act, 2013. “RESOLVED FURTHER THAT any Director of the Company and/or the Company Secretary be and is hereby jointly and/or severally authorized to do all such acts, deeds, matters and things as may be necessary, desirable or expedient to give effect and to settle any question, difficulty or doubt that may arise in this regard.” 4. Approval for Related Party Transaction(s): To consider and if thought fit, to pass, with or without modification the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to provisions of Section 188 and other applicable provisions, if any of the Companies Act, 2013 (the “Companies Act”) read with applicable provisions the Companies (Meetings of Board and its Powers) Rules, 2014 and in terms of amended regulation 23 and such other applicable provisions / regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and all other provisions of applicable laws / rules and subject to the approval / consent of such appropriate authorities as may be required, under any statute for the time being in force, if any, (including any amendment, modifications or re-enactment thereof), consent of the members of the Company be and is hereby accorded to the Company for related party transaction(s) (whether by way of an Individual Transaction or Transactions taken together or series of transactions or otherwise) entered or to be entered into with following related parties, up to the maximum per annum amounts as appended in table below against each of the related parties and on such terms and conditions as may be considered appropriate by the Board of Directors:” Sr. Name of the Related Party Relationship *Maximum Value of Transactions per annum No. (Amount in ₹ Crore) 1 Dryfruit Factory LLP LLP in which Company is partner 75 2 Aranya Consulting and Biotech LLP LLP in which Company is partner 5 (Formerly, Aranya Agri Biotech LLP) 3 Span Diagnostics LLP (Subsidiary up LLP in which Director is partner 5 to November 10, 2025) 4 Biospan Scientific LLP LLP in which Company is partner 5 5. Biospan Contamination Control Subsidiary Company 5 Solutions Private Limited *Probable value of transactions per annum “RESOLVED FURTHER that the Board be and is hereby authorised to do and perform all such acts, deeds, matters and things as may be necessary and expedient, including finalising the terms and conditions, methods and modes in respect thereof and finalising and executing necessary documents, including contract(s), scheme(s), agreement(s) and such other documents, file applications and make representations in respect thereof and seek approval from relevant authorities, including Governmental Authorities in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient, to give effect to this resolution and to settle 2 Span Divergent Limited Annual Report 2025-26 any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution.” “RESOLVED FURTHER that the Board of Directors of the Company and/or any director of the Company a [Showing first 8,000 characters — download PDF for full document]